Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $448

Benzinga · 3d ago
Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $448.